NCAI-CC New Funding Cycle Open

The NIH Center for Accelerated Innovations at Cleveland Clinic (NCAI-CC) Announces the Request for Applications (RFA) for its sixth funding cycle.  Eligible institutions are Cleveland Clinic, Case Western Reserve University, The Ohio State University, Cincinnati Children’s Hospital Medical Center, and University of Cincinnati.

The RFA can be downloaded from

Funding is available for promising emerging technologies directed towards diagnosis, treatment or management of cardiovascular, pulmonary, blood or sleep-related disorders. We are seeking projects such as therapeutics (e.g. drugs, biologics), diagnostics, diagnostic systems, devices, tools, etc., in order to facilitate their translation to commercialized products that improve patient care and enhance health.

The NCAI-CC will provide funding and project assistance to advance the development of high priority early-stage technologies within the mission areas of the NHLBI (cardiovascular, lung, blood and sleep disorders).

Expert assistance will be provided in areas required for early technology development, including commercial opportunity assessment, intellectual property, clinical and regulatory, reimbursement, business, legal and project management.

In order to be considered, please submit a Letter of Intent by August 5, 2016.
Contents of the Letter of Intent are prescribed within the RFA, and shall include:

  • Letter of Intent Information Page
  • 2 page narrative including the following elements:
    • Project Definition
    • Unmet Need, and Market Opportunity
    • Project Background
    • Project Plan and Milestones
    • References (not to exceed one page)
    • Modified biosketch for lead investigator and up to two co-investigators. Please include education, employment history, current funding, and any history of commercialization activity, patents, etc. (not to exceed 4 pages each).  The full content of the Letter of Intent shall be submitted in a single combined unlocked PDF file.

The Letter of Intent may be submitted at:
Projects will be reviewed on the following criteria: Eligibility (fit for this funding opportunity, appropriate phase of development, feasibility), Clinical Need or Opportunity, Potential for Commercial Success, and Project Scope / Plan.


August 05, 2016. Letter of Intent submission due.
August 30, 2016. Selected applicants invited to submit full applications.
October 11, 2016. Invited application submissions due.

For more information contact: Mark Low, Managing Director, at

Please let Litsa Kranias or Dorothy Air know of your potential interest in this RFA so that match possibilities can be explored.  Contact information is below.

Evangelia G. Kranias, PhD

Hanna Professor and Director

Cardiovascular Biology

Distinguished University Professor

Co-Director, Cardiovascular Center

Cardiovascular Biology


(513) 558-2377


Dorothy H. Air, PhD

Associate Vice President for

Entrepreneurial Affairs and Technology Commercialization

University of Cincinnati


(513) 558-7339